Attrition rates and predictors of long-term (> 5 year) continuation treatment with onabotulinumtoxinA intradetrusor injections

Goueli R1, Hong J1, Rodriguez D1, Lemack G1

Research Type

Clinical

Abstract Category

Overactive Bladder

Abstract 232
OAB: Neurotoxin and Imaging
Scientific Podium Short Oral Session 17
On-Demand
Detrusor Overactivity Neuropathies: Central Urgency Urinary Incontinence Overactive Bladder Spinal Cord Injury
1. University of Texas Southwestern Medical Center
Presenter
R

Ramy Goueli

Links

Abstract

Hypothesis / aims of study
Predictors of long-term continuation of therapy with intradetrusor injections of onabotulinumtoxinA (BTX) for refractory overactive bladder (OAB) are not well defined. The objective of this study was to examine the attrition rates of BTX therapy and potential demographic and urodynamic factors predictive of long-term continuation of therapy in patients with at least 5 years of follow-up.
Study design, materials and methods
We conducted an IRB-approved retrospective review of patients who underwent at least one BTX injection between December 2007 to October 2019 and had at least 5 years of follow up. Patients were instructed to continue therapy only if they perceived significant benefit. We excluded patients with history genitourinary malignancy, genitourinary fistula/malformation or previous bladder augmentation. We examined pre-injection demographic, co-morbidities, medications, ambulatory status, bladder management, and urodynamic parameters. Multivariate logistic regression was used to identify independent predictors of long-term continuation of BTX and a Kaplan Meier survival analysis was conducted to determine attrition rates.
Results
186 patients met our criteria, with 72 (38.7%) continuing therapy for at least 5 years. The mean follow-up was 6.6 ±1.9 years. Patients who continued therapy received an average of 8.3 ±4.1 injections during the 5 years of treatment. The average age of our cohort was 54.7±17.1 years, with 133 (71.5%) being female. At the time of first injection, 73 (39%) were on an OAB medication. At baseline, 87 (47%) were voiding, with 85 (46%) requiring clean intermittent catheterization or 14 (7%) using an indwelling catheter. There were 51 patients (27%) with idiopathic overactivity (iOAB). On univariate analysis, age (OR 1.022, 95% CI 1.002-1.042; p= 0.03), female gender (OR 2.930, 95% CI 1.418-6.053, p<0.01) and diagnosis of nOAB (OR 3.062, 95% CI 1.427-6.574, p<0.01) were predictive of continuing therapy. On multivariate analysis, female gender (OR 3.321, 95% CI 1.179 to 9.352, p=0.02) and diagnosis of nOAB (OR4.934; 95%CI 1.324 to 18.382, p=0.02) were predictors of continuing BTX.  There were no urodynamic or baseline questionnaire factors predictive of continuing therapy. A Kaplan Meier survival analysis is shown (Figure 1) noting significantly varying attrition rates between subgroups.
Interpretation of results
This study shows that females and patients diagnosed with neurogenic overactive bladder had an increased likelihood of continuing therapy with BTX for at least 5 years. Within the nOAB population, both genders behaved similarly with attrition rates of 57.1% in males and 55.9% in females. The most notable demonstration of the gender differences appears in the iOAB where females had an attrition rate of 70% compared to the over 90.9% attrition rate in men. Remarkably, only one male patient with iOAB continued for five years with the remainder of patients discontinuing therapy before the one-year mark. Interestingly, there was no correlation between continuation of BTX therapy with urodynamic findings or bladder management strategy.
Concluding message
This a real-world experience of BTX adherence and continuation of therapy, with over 40% of patients continue BTX therapy beyond 5 years. Female gender and a diagnosis of nOAB are predictive of a patient preference for continued
Figure 1 Figure 1: Attrition rates of self-directed intradetrusor injection of OnabotulinumtoxinA for overactive bladder
Disclosures
Funding None Clinical Trial No Subjects Human Ethics Committee University of Texas Southwestern medical center- institutional review board Helsinki Yes Informed Consent No
03/03/2021 05:20:48